非酒精性脂肪性肝病中肝损伤的脂质介质。
Lipid mediators of liver injury in nonalcoholic fatty liver disease.
机构信息
Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University School of Medicine , Indianapolis, Indiana.
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine , Indianapolis, Indiana.
出版信息
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G75-G81. doi: 10.1152/ajpgi.00170.2018. Epub 2018 Nov 1.
Abstract
Nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of histopathological phenotypes ranging from simple steatosis to more severe liver disease associated with cell injury, including nonalcoholic steatohepatitis (NASH), advanced fibrosis, and cirrhosis. Only a subset of patients with NAFLD develop NASH from yet incompletely understood mechanisms. Emerging data suggest lipid species other than triglycerides as contributors to the pathogenesis of NASH. In this mini review, we focus on the recent data on the mechanisms of NASH, focusing on these lipid mediators and their potential as therapeutic targets in NASH.
摘要
非酒精性脂肪性肝病（NAFLD）包括一系列组织病理学表型，从单纯性脂肪变性到与细胞损伤相关的更严重肝病，包括非酒精性脂肪性肝炎（NASH）、进展性肝纤维化和肝硬化。只有一小部分 NAFLD 患者从尚未完全了解的机制中发展为 NASH。新出现的数据表明，除甘油三酯以外的脂质种类也可能参与 NASH 的发病机制。在这篇迷你综述中，我们重点关注 NASH 发病机制的最新数据，重点介绍这些脂质介质及其作为 NASH 治疗靶点的潜力。
相似文献
1
Lipid mediators of liver injury in nonalcoholic fatty liver disease.
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G75-G81. doi: 10.1152/ajpgi.00170.2018. Epub 2018 Nov 1.
2
Nonalcoholic Fatty Liver Disease: Basic Pathogenetic Mechanisms in the Progression From NAFLD to NASH.
Transplantation. 2019 Jan;103(1):e1-e13. doi: 10.1097/TP.0000000000002480.
3
Nonalcoholic Steatohepatitis.
Annu Rev Med. 2017 Jan 14;68:85-98. doi: 10.1146/annurev-med-051215-031109. Epub 2016 Oct 5.
4
Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Free Radic Biol Med. 2017 Oct;111:173-185. doi: 10.1016/j.freeradbiomed.2017.01.023. Epub 2017 Jan 18.
5
Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Oncotarget. 2016 Jul 5;7(27):42762-42776. doi: 10.18632/oncotarget.8641.
6
Potential Therapeutic Application of Estrogen in Gender Disparity of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.
Cells. 2019 Oct 15;8(10):1259. doi: 10.3390/cells8101259.
7
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.
8
Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2014 Nov 14;20(42):15539-48. doi: 10.3748/wjg.v20.i42.15539.
9
Lipidomics in pathogenesis, progression and treatment of nonalcoholic steatohepatitis (NASH): Recent advances.
Prog Lipid Res. 2023 Jul;91:101238. doi: 10.1016/j.plipres.2023.101238. Epub 2023 May 25.
10
Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Am J Physiol Gastrointest Liver Physiol. 2019 Apr 1;316(4):G462-G472. doi: 10.1152/ajpgi.00358.2018. Epub 2019 Jan 17.
引用本文的文献
1
Circulating glycerate predicts resilience to fructose-induced hepatic steatosis.
Cell Metab. 2025 May 6;37(5):1223-1234.e5. doi: 10.1016/j.cmet.2025.03.017. Epub 2025 Apr 22.
2
Tspo Depletion Exacerbates Steatosis Through Fatty Acid Uptake.
J Cell Mol Med. 2025 Apr;29(7):e70500. doi: 10.1111/jcmm.70500.
3
Impaired RelA signaling and lipid metabolism dysregulation in hepatocytes: driving forces in the progression of metabolic dysfunction-associated steatotic liver disease.
Cell Death Discov. 2025 Feb 5;11(1):49. doi: 10.1038/s41420-025-02312-3.
4
Alanine aminotransferase as a risk marker for new-onset metabolic dysfunction-associated fatty liver disease.
World J Gastroenterol. 2024 Jul 7;30(25):3132-3139. doi: 10.3748/wjg.v30.i25.3132.
5
Exploring the Role of Bempedoic Acid in Metabolic Dysfunction Associated Steatotic Liver Disease: Actual Evidence and Future Perspectives.
Int J Mol Sci. 2024 Jun 25;25(13):6938. doi: 10.3390/ijms25136938.
6
Pseudotargeted lipidomics analysis of scoparone on glycerophospholipid metabolism in non-alcoholic steatohepatitis mice by LC-MRM-MS.
PeerJ. 2024 May 21;12:e17380. doi: 10.7717/peerj.17380. eCollection 2024.
7
Lipidome Changes Associated with a Diet-Induced Reduction in Hepatic Fat among Adolescent Boys with Metabolic Dysfunction-Associated Steatotic Liver Disease.
Metabolites. 2024 Mar 28;14(4):191. doi: 10.3390/metabo14040191.
8
Effect of herbal extracts and Saroglitazar on high-fat diet-induced obesity, insulin resistance, dyslipidemia, and hepatic lipidome in C57BL/6J mice.
Heliyon. 2023 Nov 4;9(11):e22051. doi: 10.1016/j.heliyon.2023.e22051. eCollection 2023 Nov.
9
Anti-Inflammatory and Therapeutic Effects of a Novel Small-Molecule Inhibitor of Inflammation in a Male C57BL/6J Mouse Model of Obesity-Induced NAFLD/MAFLD.
J Inflamm Res. 2023 Nov 16;16:5339-5366. doi: 10.2147/JIR.S413565. eCollection 2023.
10
Hyperglycemia and Hyperlipidemia with Kidney or Liver Transplantation: A Review.
Biology (Basel). 2023 Aug 29;12(9):1185. doi: 10.3390/biology12091185.
本文引用的文献
1
Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease.
J Lipid Res. 2019 Jan;60(1):176-185. doi: 10.1194/jlr.P089953. Epub 2018 Oct 15.
2
A Protein-Truncating HSD17B13 Variant and Protection from Chronic Liver Disease.
N Engl J Med. 2018 Mar 22;378(12):1096-1106. doi: 10.1056/NEJMoa1712191.
3
Lipotoxicity and the gut-liver axis in NASH pathogenesis.
J Hepatol. 2018 Feb;68(2):280-295. doi: 10.1016/j.jhep.2017.11.014. Epub 2017 Nov 14.
4
Molecular mechanisms of nonalcoholic fatty liver disease: Potential role for 12-lipoxygenase.
J Diabetes Complications. 2017 Nov;31(11):1630-1637. doi: 10.1016/j.jdiacomp.2017.07.014. Epub 2017 Jul 31.
5
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.
Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29.
6
Novel association of rs58542926 genotype with increased serum tyrosine levels and decreased apoB-100 particles in Finns.
J Lipid Res. 2017 Jul;58(7):1471-1481. doi: 10.1194/jlr.P076034. Epub 2017 May 24.
7
Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH.
J Lipid Res. 2017 Jun;58(6):1067-1079. doi: 10.1194/jlr.M072454. Epub 2017 Apr 12.
8
Modeling fatty liver disease in animals: Is there an optimal approach, and is the effort worthwhile?
Hepatology. 2016 Nov;64(5):1398-1400. doi: 10.1002/hep.28823. Epub 2016 Sep 30.
9
Featured Article: Alterations of lecithin cholesterol acyltransferase activity and apolipoprotein A-I functionality in human sickle blood.
Exp Biol Med (Maywood). 2016 Nov;241(17):1933-1942. doi: 10.1177/1535370216657447. Epub 2016 Jun 27.
10
Novel Molecular Mechanisms in the Development of Non-Alcoholic Steatohepatitis.
Diabetes Metab J. 2016 Feb;40(1):1-11. doi: 10.4093/dmj.2016.40.1.1.
Zotero 插件